Login / Signup

Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study.

Laura Jayne BonnettGraham A PowellCatrin Tudur SmithAnthony G Marson
Published in: PloS one (2017)
This is the first analysis to consider risk of a breakthrough seizure and subsequent outcomes. The described models can be used to identify people most likely to have a breakthrough seizure, a seizure recurrence following a breakthrough seizure, and to achieve 12-month remission following a breakthrough seizure. The results suggest that focussing on achieving 12-month remission swiftly represents the best therapeutic aim to reduce the risk of a breakthrough seizure and subsequent negative outcomes. This will aid individual patient risk stratification and the design of future epilepsy trials.
Keyphrases
  • temporal lobe epilepsy
  • disease activity
  • type diabetes
  • rheumatoid arthritis
  • metabolic syndrome
  • skeletal muscle
  • data analysis